Pulmonary Arterial Hypertension (PAH) Market Report

China Pulmonary Arterial Hypertension (PAH) Market Professional Research Report 2022-2027, Segmented by Players, Types, End-Users in Major Regions

  • POSTDATE：Aug 22, 2022
  • PAGES：235
  • REPORT CODE：GMM1101123
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Pulmonary hypertension is a condition of increased blood pressure within the arteries of the lungs.[6] Symptoms include shortness of breath, syncope, tiredness, chest pain, swelling of the legs, and a fast heartbeat.

    This report offers an overview of the market trends, drivers, and barriers with respect to the China Pulmonary Arterial Hypertension (PAH) market. It also provides a detailed overview of the market of different regions across North China, Central China, South China, East China, Northeast China, Southwest China, Northwest China. The report deep analyzes type and application in China Pulmonary Arterial Hypertension (PAH) market. Detailed analysis of key players, along with key growth strategies adopted by Pulmonary Arterial Hypertension (PAH) industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.

    By Player:

    • Pfizer

    • United Therapeutics

    • Arena

    • Gilead Sciences

    • Bayer

    • Actelion

    • GlaxoSmithKline

    By Type:

    • Prostacyclin and Prostacyclin Analogs

    • SGC Stimulators

    • ERA

    • PDE-5

    By End-User:

    • Hospital

    • Clinic

    By Region:

    • North China

    • Central China

    • South China

    • East China

    • Northeast China

    • Southwest China

    • Northwest China

  • TABLE OF CONTENT

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Pulmonary Arterial Hypertension (PAH) Market

    • 1.3 Market Segment by Type

    • 1.3.1 China Pulmonary Arterial Hypertension (PAH) Market Size and Growth Rate of Prostacyclin and Prostacyclin Analogs from 2016 to 2027

    • 1.3.2 China Pulmonary Arterial Hypertension (PAH) Market Size and Growth Rate of SGC Stimulators from 2016 to 2027

    • 1.3.3 China Pulmonary Arterial Hypertension (PAH) Market Size and Growth Rate of ERA from 2016 to 2027

    • 1.3.4 China Pulmonary Arterial Hypertension (PAH) Market Size and Growth Rate of PDE-5 from 2016 to 2027

    • 1.4 Market Segment by Application

    • 1.4.1 China Pulmonary Arterial Hypertension (PAH) Market Size and Growth Rate of Hospital from 2016 to 2027

    • 1.4.2 China Pulmonary Arterial Hypertension (PAH) Market Size and Growth Rate of Clinic from 2016 to 2027

    • 1.5 Market Segment by Regions

      • 1.5.1 North China Pulmonary Arterial Hypertension (PAH) Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.2 Central China Pulmonary Arterial Hypertension (PAH) Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.3 South China Pulmonary Arterial Hypertension (PAH) Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.4 East China Pulmonary Arterial Hypertension (PAH) Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.5 Northeast China Pulmonary Arterial Hypertension (PAH) Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.6 Southwest China Pulmonary Arterial Hypertension (PAH) Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.7 Northwest China Pulmonary Arterial Hypertension (PAH) Consumption Market Size and Growth Rate from 2016 to 2027

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    • 2.3 Coronavirus (COVID-19) Distribution and its Impact on the Industry

    3 Segmentation of Pulmonary Arterial Hypertension (PAH) Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Vendors

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Pulmonary Arterial Hypertension (PAH) by Major Types

    • 3.4.1 Market Size and Growth Rate of Prostacyclin and Prostacyclin Analogs

    • 3.4.2 Market Size and Growth Rate of SGC Stimulators

    • 3.4.3 Market Size and Growth Rate of ERA

    • 3.4.4 Market Size and Growth Rate of PDE-5

    4 Segmentation of Pulmonary Arterial Hypertension (PAH) Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Pulmonary Arterial Hypertension (PAH) by Major End-Users

    • 4.4.1 Market Size and Growth Rate of Pulmonary Arterial Hypertension (PAH) in Hospital

    • 4.4.2 Market Size and Growth Rate of Pulmonary Arterial Hypertension (PAH) in Clinic

    5 Market Analysis by Regions

    • 5.1 China Pulmonary Arterial Hypertension (PAH) Production Analysis by Regions

    • 5.2 China Pulmonary Arterial Hypertension (PAH) Consumption Analysis by Regions

    • 5.3 Coronavirus (COVID-19) Impact on China Economy

    6 North China Pulmonary Arterial Hypertension (PAH) Landscape Analysis

    • 6.1 North China Pulmonary Arterial Hypertension (PAH) Landscape Analysis by Major Types

    • 6.2 North China Pulmonary Arterial Hypertension (PAH) Landscape Analysis by Major End-Users

    7 Central China Pulmonary Arterial Hypertension (PAH) Landscape Analysis

    • 7.1 Central China Pulmonary Arterial Hypertension (PAH) Landscape Analysis by Major Types

    • 7.2 Central China Pulmonary Arterial Hypertension (PAH) Landscape Analysis by Major End-Users

    8 South China Pulmonary Arterial Hypertension (PAH) Landscape Analysis

    • 8.1 South China Pulmonary Arterial Hypertension (PAH) Landscape Analysis by Major Types

    • 8.2 South China Pulmonary Arterial Hypertension (PAH) Landscape Analysis by Major End-Users

    9 East China Pulmonary Arterial Hypertension (PAH) Landscape Analysis

    • 9.1 East China Pulmonary Arterial Hypertension (PAH) Landscape Analysis by Major Types

    • 9.2 East China Pulmonary Arterial Hypertension (PAH) Landscape Analysis by Major End-Users

    10 Northeast China Pulmonary Arterial Hypertension (PAH) Landscape Analysis

    • 10.1 Northeast China Pulmonary Arterial Hypertension (PAH) Landscape Analysis by Major Types

    • 10.2 Northeast China Pulmonary Arterial Hypertension (PAH) Landscape Analysis by Major End-Users

    11 Southwest China Pulmonary Arterial Hypertension (PAH) Landscape Analysis

    • 11.1 Southwest China Pulmonary Arterial Hypertension (PAH) Landscape Analysis by Major Types

    • 11.2 Southwest China Pulmonary Arterial Hypertension (PAH) Landscape Analysis by Major End-Users

    12 Northwest China Pulmonary Arterial Hypertension (PAH) Landscape Analysis

    • 12.1 Northwest China Pulmonary Arterial Hypertension (PAH) Landscape Analysis by Major Types

    • 12.2 Northwest China Pulmonary Arterial Hypertension (PAH) Landscape Analysis by Major End-Users

    13 Major Players Profiles

    • 13.1 Pfizer

      • 13.1.1 Pfizer Company Profile and Recent Development

      • 13.1.2 Market Performance

      • 13.1.3 Product and Service Introduction

    • 13.2 United Therapeutics

      • 13.2.1 United Therapeutics Company Profile and Recent Development

      • 13.2.2 Market Performance

      • 13.2.3 Product and Service Introduction

    • 13.3 Arena

      • 13.3.1 Arena Company Profile and Recent Development

      • 13.3.2 Market Performance

      • 13.3.3 Product and Service Introduction

    • 13.4 Gilead Sciences

      • 13.4.1 Gilead Sciences Company Profile and Recent Development

      • 13.4.2 Market Performance

      • 13.4.3 Product and Service Introduction

    • 13.5 Bayer

      • 13.5.1 Bayer Company Profile and Recent Development

      • 13.5.2 Market Performance

      • 13.5.3 Product and Service Introduction

    • 13.6 Actelion

      • 13.6.1 Actelion Company Profile and Recent Development

      • 13.6.2 Market Performance

      • 13.6.3 Product and Service Introduction

    • 13.7 GlaxoSmithKline

      • 13.7.1 GlaxoSmithKline Company Profile and Recent Development

      • 13.7.2 Market Performance

      • 13.7.3 Product and Service Introduction

    The List of Tables and Figures

    • Figure Product Picture

    • Figure China Pulmonary Arterial Hypertension (PAH) Market Size and Growth Rate of Prostacyclin and Prostacyclin Analogs from 2016 to 2027

    • Figure China Pulmonary Arterial Hypertension (PAH) Market Size and Growth Rate of SGC Stimulators from 2016 to 2027

    • Figure China Pulmonary Arterial Hypertension (PAH) Market Size and Growth Rate of ERA from 2016 to 2027

    • Figure China Pulmonary Arterial Hypertension (PAH) Market Size and Growth Rate of PDE-5 from 2016 to 2027

    • Figure Market Share by Type in 2016

    • Figure Market Share by Type in 2021

    • Figure Market Share by Type in 2027

    • Figure China Pulmonary Arterial Hypertension (PAH) Market Size and Growth Rate of Hospital from 2016 to 2027

    • Figure China Pulmonary Arterial Hypertension (PAH) Market Size and Growth Rate of Clinic from 2016 to 2027

    • Figure Market Share by End-User in 2016

    • Figure Market Share by End-User in 2021

    • Figure Market Share by End-User in 2027

    • Figure North China Pulmonary Arterial Hypertension (PAH) Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Central China Pulmonary Arterial Hypertension (PAH) Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure South China Pulmonary Arterial Hypertension (PAH) Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure East China Pulmonary Arterial Hypertension (PAH) Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Northeast China Pulmonary Arterial Hypertension (PAH) Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Southwest China Pulmonary Arterial Hypertension (PAH) Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Northwest China Pulmonary Arterial Hypertension (PAH) Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Development Trends and Industry Dynamics of Pulmonary Arterial Hypertension (PAH) Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 3 Players in 2020

    • Figure Market Share of TOP 5 Players in 2021

    • Figure Market Share of TOP 6 Players from 2016 to 2021

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Figure Coronavirus (COVID-19) Map of China

    • Table Coronavirus (COVID-19) Impact on the Industry

    • Figure Specifications of Different Types of Pulmonary Arterial Hypertension (PAH)

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Pulmonary Arterial Hypertension (PAH) by Different Types from 2016 to 2027

    • Table Consumption Share of Pulmonary Arterial Hypertension (PAH) by Different Types from 2016 to 2027

    • Figure Market Size and Growth Rate of Prostacyclin and Prostacyclin Analogs

    • Figure Market Size and Growth Rate of SGC Stimulators

    • Figure Market Size and Growth Rate of ERA

    • Figure Market Size and Growth Rate of PDE-5

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Figure Consumption of Pulmonary Arterial Hypertension (PAH) by Different End-Users from 2016 to 2027

    • Table Consumption Share of Pulmonary Arterial Hypertension (PAH) by Different End-Users from 2016 to 2027

    • Figure Market Size and Growth Rate of Hospital

    • Figure Market Size and Growth Rate of Clinic

    • Table China Pulmonary Arterial Hypertension (PAH) Production by Regions

    • Table China Pulmonary Arterial Hypertension (PAH) Production Share by Regions

    • Figure China Pulmonary Arterial Hypertension (PAH) Production Share by Regions in 2016

    • Figure China Pulmonary Arterial Hypertension (PAH) Production Share by Regions in 2021

    • Figure China Pulmonary Arterial Hypertension (PAH) Production Share by Regions in 2027

    • Table China Pulmonary Arterial Hypertension (PAH) Consumption by Regions

    • Table China Pulmonary Arterial Hypertension (PAH) Consumption Share by Regions

    • Figure China Pulmonary Arterial Hypertension (PAH) Consumption Share by Regions in 2016

    • Figure China Pulmonary Arterial Hypertension (PAH) Consumption Share by Regions in 2021

    • Figure China Pulmonary Arterial Hypertension (PAH) Consumption Share by Regions in 2027

    • Table North China Pulmonary Arterial Hypertension (PAH) Consumption by Types from 2016 to 2027

    • Table North China Pulmonary Arterial Hypertension (PAH) Consumption Share by Types from 2016 to 2027

    • Figure North China Pulmonary Arterial Hypertension (PAH) Consumption Share by Types in 2016

    • Figure North China Pulmonary Arterial Hypertension (PAH) Consumption Share by Types in 2021

    • Figure North China Pulmonary Arterial Hypertension (PAH) Consumption Share by Types in 2027

    • Table North China Pulmonary Arterial Hypertension (PAH) Consumption by End-Users from 2016 to 2027

    • Table North China Pulmonary Arterial Hypertension (PAH) Consumption Share by End-Users from 2016 to 2027

    • Figure North China Pulmonary Arterial Hypertension (PAH) Consumption Share by End-Users in 2016

    • Figure North China Pulmonary Arterial Hypertension (PAH) Consumption Share by End-Users in 2021

    • Figure North China Pulmonary Arterial Hypertension (PAH) Consumption Share by End-Users in 2027

    • Table Central China Pulmonary Arterial Hypertension (PAH) Consumption by Types from 2016 to 2027

    • Table Central China Pulmonary Arterial Hypertension (PAH) Consumption Share by Types from 2016 to 2027

    • Figure Central China Pulmonary Arterial Hypertension (PAH) Consumption Share by Types in 2016

    • Figure Central China Pulmonary Arterial Hypertension (PAH) Consumption Share by Types in 2021

    • Figure Central China Pulmonary Arterial Hypertension (PAH) Consumption Share by Types in 2027

    • Table Central China Pulmonary Arterial Hypertension (PAH) Consumption by End-Users from 2016 to 2027

    • Table Central China Pulmonary Arterial Hypertension (PAH) Consumption Share by End-Users from 2016 to 2027

    • Figure Central China Pulmonary Arterial Hypertension (PAH) Consumption Share by End-Users in 2016

    • Figure Central China Pulmonary Arterial Hypertension (PAH) Consumption Share by End-Users in 2021

    • Figure Central China Pulmonary Arterial Hypertension (PAH) Consumption Share by End-Users in 2027

    • Table South China Pulmonary Arterial Hypertension (PAH) Consumption by Types from 2016 to 2027

    • Table South China Pulmonary Arterial Hypertension (PAH) Consumption Share by Types from 2016 to 2027

    • Figure South China Pulmonary Arterial Hypertension (PAH) Consumption Share by Types in 2016

    • Figure South China Pulmonary Arterial Hypertension (PAH) Consumption Share by Types in 2021

    • Figure South China Pulmonary Arterial Hypertension (PAH) Consumption Share by Types in 2027

    • Table South China Pulmonary Arterial Hypertension (PAH) Consumption by End-Users from 2016 to 2027

    • Table South China Pulmonary Arterial Hypertension (PAH) Consumption Share by End-Users from 2016 to 2027

    • Figure South China Pulmonary Arterial Hypertension (PAH) Consumption Share by End-Users in 2016

    • Figure South China Pulmonary Arterial Hypertension (PAH) Consumption Share by End-Users in 2021

    • Figure South China Pulmonary Arterial Hypertension (PAH) Consumption Share by End-Users in 2027

    • Table East China Pulmonary Arterial Hypertension (PAH) Consumption by Types from 2016 to 2027

    • Table East China Pulmonary Arterial Hypertension (PAH) Consumption Share by Types from 2016 to 2027

    • Figure East China Pulmonary Arterial Hypertension (PAH) Consumption Share by Types in 2016

    • Figure East China Pulmonary Arterial Hypertension (PAH) Consumption Share by Types in 2021

    • Figure East China Pulmonary Arterial Hypertension (PAH) Consumption Share by Types in 2027

    • Table East China Pulmonary Arterial Hypertension (PAH) Consumption by End-Users from 2016 to 2027

    • Table East China Pulmonary Arterial Hypertension (PAH) Consumption Share by End-Users from 2016 to 2027

    • Figure East China Pulmonary Arterial Hypertension (PAH) Consumption Share by End-Users in 2016

    • Figure East China Pulmonary Arterial Hypertension (PAH) Consumption Share by End-Users in 2021

    • Figure East China Pulmonary Arterial Hypertension (PAH) Consumption Share by End-Users in 2027

    • Table Northeast China Pulmonary Arterial Hypertension (PAH) Consumption by Types from 2016 to 2027

    • Table Northeast China Pulmonary Arterial Hypertension (PAH) Consumption Share by Types from 2016 to 2027

    • Figure Northeast China Pulmonary Arterial Hypertension (PAH) Consumption Share by Types in 2016

    • Figure Northeast China Pulmonary Arterial Hypertension (PAH) Consumption Share by Types in 2021

    • Figure Northeast China Pulmonary Arterial Hypertension (PAH) Consumption Share by Types in 2027

    • Table Northeast China Pulmonary Arterial Hypertension (PAH) Consumption by End-Users from 2016 to 2027

    • Table Northeast China Pulmonary Arterial Hypertension (PAH) Consumption Share by End-Users from 2016 to 2027

    • Figure Northeast China Pulmonary Arterial Hypertension (PAH) Consumption Share by End-Users in 2016

    • Figure Northeast China Pulmonary Arterial Hypertension (PAH) Consumption Share by End-Users in 2021

    • Figure Northeast China Pulmonary Arterial Hypertension (PAH) Consumption Share by End-Users in 2027

    • Table Southwest China Pulmonary Arterial Hypertension (PAH) Consumption by Types from 2016 to 2027

    • Table Southwest China Pulmonary Arterial Hypertension (PAH) Consumption Share by Types from 2016 to 2027

    • Figure Southwest China Pulmonary Arterial Hypertension (PAH) Consumption Share by Types in 2016

    • Figure Southwest China Pulmonary Arterial Hypertension (PAH) Consumption Share by Types in 2021

    • Figure Southwest China Pulmonary Arterial Hypertension (PAH) Consumption Share by Types in 2027

    • Table Southwest China Pulmonary Arterial Hypertension (PAH) Consumption by End-Users from 2016 to 2027

    • Table Southwest China Pulmonary Arterial Hypertension (PAH) Consumption Share by End-Users from 2016 to 2027

    • Figure Southwest China Pulmonary Arterial Hypertension (PAH) Consumption Share by End-Users in 2016

    • Figure Southwest China Pulmonary Arterial Hypertension (PAH) Consumption Share by End-Users in 2021

    • Figure Southwest China Pulmonary Arterial Hypertension (PAH) Consumption Share by End-Users in 2027

    • Table Northwest China Pulmonary Arterial Hypertension (PAH) Consumption by Types from 2016 to 2027

    • Table Northwest China Pulmonary Arterial Hypertension (PAH) Consumption Share by Types from 2016 to 2027

    • Figure Northwest China Pulmonary Arterial Hypertension (PAH) Consumption Share by Types in 2016

    • Figure Northwest China Pulmonary Arterial Hypertension (PAH) Consumption Share by Types in 2021

    • Figure Northwest China Pulmonary Arterial Hypertension (PAH) Consumption Share by Types in 2027

    • Table Northwest China Pulmonary Arterial Hypertension (PAH) Consumption by End-Users from 2016 to 2027

    • Table Northwest China Pulmonary Arterial Hypertension (PAH) Consumption Share by End-Users from 2016 to 2027

    • Figure Northwest China Pulmonary Arterial Hypertension (PAH) Consumption Share by End-Users in 2016

    • Figure Northwest China Pulmonary Arterial Hypertension (PAH) Consumption Share by End-Users in 2021

    • Figure Northwest China Pulmonary Arterial Hypertension (PAH) Consumption Share by End-Users in 2027

    • Table Company Profile and Development Status of Pfizer

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Pfizer

    • Figure Sales and Growth Rate Analysis of Pfizer

    • Figure Revenue and Market Share Analysis of Pfizer

    • Table Product and Service Introduction of Pfizer

    • Table Company Profile and Development Status of United Therapeutics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of United Therapeutics

    • Figure Sales and Growth Rate Analysis of United Therapeutics

    • Figure Revenue and Market Share Analysis of United Therapeutics

    • Table Product and Service Introduction of United Therapeutics

    • Table Company Profile and Development Status of Arena

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Arena

    • Figure Sales and Growth Rate Analysis of Arena

    • Figure Revenue and Market Share Analysis of Arena

    • Table Product and Service Introduction of Arena

    • Table Company Profile and Development Status of Gilead Sciences

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Gilead Sciences

    • Figure Sales and Growth Rate Analysis of Gilead Sciences

    • Figure Revenue and Market Share Analysis of Gilead Sciences

    • Table Product and Service Introduction of Gilead Sciences

    • Table Company Profile and Development Status of Bayer

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Bayer

    • Figure Sales and Growth Rate Analysis of Bayer

    • Figure Revenue and Market Share Analysis of Bayer

    • Table Product and Service Introduction of Bayer

    • Table Company Profile and Development Status of Actelion

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Actelion

    • Figure Sales and Growth Rate Analysis of Actelion

    • Figure Revenue and Market Share Analysis of Actelion

    • Table Product and Service Introduction of Actelion

    • Table Company Profile and Development Status of GlaxoSmithKline

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of GlaxoSmithKline

    • Figure Sales and Growth Rate Analysis of GlaxoSmithKline

    • Figure Revenue and Market Share Analysis of GlaxoSmithKline

    • Table Product and Service Introduction of GlaxoSmithKline


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US